Clinical Trial Update: Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Years [Phase 2]

View source ↗

Summary

A Phase 2 trial of Caelyx as first-line therapy for breast cancer in patients with cardiovascular risk factors or age over 65 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Caelyx (liposomal doxorubicin)

Snippet

Sponsor: SOLTI Breast Cancer Research Group | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED